GHRP-6
GHRP-6 is a growth hormone releasing peptide that triggers a short GH pulse through the ghrelin receptor.
We have not published an audit on GHRP-6. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Activates the ghrelin receptor (GHS-R1a) to trigger a natural GH pulse. [Source: Peptide Dosing Protocols]
GHRP-6 is a synthetic six-amino-acid peptide that activates the ghrelin receptor in the body to prompt the pituitary gland to release a pulse of its own growth hormone, and its most notable side effect is intense hunger shortly after dosing.
Reported side effects
The most common effects of GHRP-6 include intense hunger shortly after dosing, water retention, tingling or numbness in the hands, brief flushing or head-rush, and tiredness, with higher doses also raising cortisol and prolactin and potentially affecting blood sugar.
Who should avoid it
People with diabetes, insulin resistance, active or prior cancer, those who are pregnant or breastfeeding, and competitive athletes should avoid GHRP-6 or only use it under close medical supervision.
What gets monitored
Track IGF-1 and fasting glucose if relevant. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for GHRP-6 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 300 mcg · Low: 100 mcg · High: 300 mcg | 3x daily, at least 4 hours apartnull · 8 weeks on, 4 weeks off | SubQ | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: null. GHRP-6 is typically dosed at 100-300 mcg per injection. |
| Cycling reference: 6-8 weeks on, 4 weeks off. Cited for appetite stimulation and GH release with fat metabolism support. | not statedOn-cycle 6-8 weeks, off-cycle 4 weeks | subcutaneous | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- 3x daily, at least 4 hours apartnull · 8 weeks on, 4 weeks off
- SubQ
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: null. GHRP-6 is typically dosed at 100-300 mcg per injection.
- not statedOn-cycle 6-8 weeks, off-cycle 4 weeks
- subcutaneous
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- 3 mL bacteriostatic water
Common questions
What is GHRP-6?
GHRP-6 is a synthetic six-amino-acid peptide that activates the ghrelin receptor and signals the pituitary to release a pulse of your own growth hormone.
What is GHRP-6 used for?
In research, it is used to study growth hormone release and was used as a tool to test pituitary GH reserve.
How is GHRP-6 dosed?
Research-use discussions usually describe 100-300 mcg per SubQ injection on an empty stomach, often three times daily.
GHRP-2 vs GHRP-6: what is the difference?
GHRP-2 releases more GH per microgram and causes less hunger, while GHRP-6 causes the strongest appetite.
GHRP-6 vs ipamorelin: which is cleaner?
Ipamorelin is usually called the cleaner option because it releases GH without meaningful appetite, cortisol, or prolactin effects.
Does GHRP-6 build muscle?
On its own, the evidence for meaningful muscle gain is weak, and the GH rise is modest next to injectable HGH.
What are the side effects of GHRP-6?
The biggest one is intense hunger, with others including water retention, tingling, and tiredness.
How do you reconstitute GHRP-6?
For a common 5 mg vial, adding 3 mL of bacteriostatic water gives about 1,667 mcg/mL.
Check 5 mg in 3 mL in the calculator →Sources
- 01Bowers CY, Momany FA, Reynolds GA, Hong A On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology (1984)
- 02Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996)
- 03Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999)
- 04Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin in humans: comparison with GHRP-6 and GHRP-2 (GH, ACTH, cortisol, prolactin). Journal of Clinical Endocrinology & Metabolism (2001)
- 05Leal-Cerro A, Pereira JL, Garcia-Luna PP, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. Journal of Clinical Endocrinology & Metabolism (1998)
- 06Berlanga-Acosta J, Abreu-Cruz A, Garcia-Ojalvo A, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology (2017)
- 07Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences USA (1995)
- 08Kojima M, Kangawa K Ghrelin: structure and function. Physiological Reviews (2005)
- 09World Anti-Doping Agency Prohibited List, Section S2: Peptide Hormones, Growth Factors, Related Substances (growth hormone secretagogues). WADA (2026)
- 10U.S. Food & Drug Administration Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA (2026)
The reference sections above are imported from our compound knowledge base, which classes the evidence for GHRP-6 as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
AOD9604 is a modified C-terminal fragment of human growth hormone (residues 176-191), studied in lipid metabolism research models.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.